This Tiny Molecule Might Explain Why We Age

There was a time when NAD+ lived a quiet, respectable life inside biology textbooks, minding its own business between diagrams of mitochondria and polite explanations of cellular respiration. The molecule itself was first identified in 1906 by British biochemists Arthur Harden and William John Young while studying fermentation in yeast, and later characterised in more detail by Otto Warburg, who would go on to win the Nobel Prize in 1931. For most of the 20th century, NAD+ remained firmly in the domain of biochemistry. Then, almost overnight, it escaped the lab and found itself rebranded as something far more glamorous: the molecule that might hold the secret to ageing. Not bad for a compound most people couldn’t pronounce five years ago.

At its simplest, NAD+ is a coenzyme present in every living cell, with estimated intracellular concentrations ranging from around 0.2 to 0.5 millimolar depending on tissue type. That sounds technical, but the reality is far more grounded. It helps your body turn food into energy. Every time you eat, move, think, or even sit still pretending to be productive, NAD+ is involved somewhere in the background, passing electrons around like a courier who never gets credit. In a typical human cell, thousands of redox reactions per second depend on this NAD+/NADH cycling.

Without it, your cells wouldn’t generate ATP, which is essentially the fuel that keeps everything running. No ATP, no energy. No energy, no anything. It’s less of a wellness trend and more of a biological non-negotiable.

The real intrigue begins when you look at how NAD+ behaves over time. Levels of it decline as we age. Not dramatically overnight, but steadily. Studies suggest that NAD+ levels in certain tissues can fall by as much as 40–50% between early adulthood and old age. This mirrors many of the things people associate with getting older: reduced energy, slower recovery, less efficient metabolism. Suddenly, a molecule that once sat comfortably in the background starts looking suspiciously important.

Researchers have known this for a while, but the story gained momentum in the early 2000s when scientists began linking NAD+ to a group of proteins called sirtuins, first studied in yeast by Leonard Guarente at MIT. These proteins regulate cellular health, stress responses, and, rather inconveniently for anyone trying to keep expectations modest, aspects of ageing itself. NAD+ is required to activate them. No NAD+, no sirtuin activity. It’s a bit like having a sophisticated control system with no electricity to run it.

At this point, the narrative writes itself. If NAD+ declines with age, and if it supports systems that keep cells functioning well, then boosting NAD+ should, in theory, help maintain those systems. That’s the idea that launched a thousand supplements.

Enter NMN and NR, two compounds that sound like airport codes but are marketed as precursors to NAD+. The pitch is straightforward: take these, your body converts them into NAD+, and everything from your energy levels to your biological age might benefit. It’s an appealing proposition, especially in a culture that prefers capsules over lifestyle adjustments.

The science, however, is slightly less enthusiastic. In animal studies, increasing NAD+ levels has produced impressive results. A widely cited 2013 study by David Sinclair’s group at Harvard showed that boosting NAD+ in older mice improved mitochondrial function and reversed certain markers of ageing within a week. Other studies have reported improved insulin sensitivity and endurance in rodents. It’s the kind of data that fuels headlines and investment decks in equal measure.

Human studies tell a more restrained story. Trials on nicotinamide riboside, including a 2016 study published in Nature Communications, showed that supplementation can safely increase NAD+ levels in humans by up to 60%, depending on dosage. However, measurable clinical benefits remain modest, particularly in healthy individuals. There are signs of improvement in metabolic health and muscle function, but the effects are far from transformative. More importantly, long-term outcomes remain unclear. Biology rarely rewards shortcuts, and when it does, it tends to send the invoice later.

That hasn’t stopped the wellness industry from moving quickly. NAD+ infusions, for instance, have become a fixture in certain urban clinics, with sessions often costing between £300 and £1,000 depending on dosage and location. The idea of sitting in a comfortable chair while a drip promises improved energy, sharper thinking, and perhaps a subtle rewind of the ageing process has a certain appeal. It feels proactive, almost strategic, like outsourcing your cellular maintenance.

Whether it works in a meaningful, measurable way is another question. Evidence is limited, and much of the enthusiasm is anecdotal. People report feeling better, which is not nothing, but also not the same as proof. Placebo is a powerful collaborator.

Meanwhile, the less glamorous methods of supporting NAD+ continue to exist, largely ignored because they lack packaging. Exercise, for example, has been shown to influence NAD+ levels. So has sleep. Even calorie intake plays a role. These are not new ideas, which may explain why they struggle to compete with something that comes in a sleek bottle and promises efficiency.

Diet matters as well, though not in the way marketing might suggest. You don’t really consume NAD+ directly in meaningful amounts, but you can provide the building blocks your body needs to produce it. Foods rich in vitamin B3 (niacin), such as chicken, tuna, and mushrooms, contribute to this process, with recommended daily intake in the UK set at around 16 mg for men and 14 mg for women. Tryptophan, found in eggs and dairy, offers another pathway via the kynurenine route. It’s less dramatic than a supplement regimen, but also more aligned with how the body actually operates.

There’s also a broader question quietly sitting behind all of this: are we trying to fix ageing, or are we trying to make it look more manageable? NAD+ sits at an interesting intersection of those ambitions. It’s essential, undeniably. It’s involved in processes that decline over time. But it’s not a lever you can pull in isolation and expect the entire system to reset.

That hasn’t stopped certain figures from leaning into the narrative. The field has its advocates, including Harvard geneticist David Sinclair, whose 2019 book Lifespan helped bring NAD+ into mainstream attention, as well as researchers like Shin-ichiro Imai at Washington University, who has studied NAD+ metabolism extensively. The line between research and optimism can blur, particularly when there’s commercial interest involved. Allied Market Research projects the global anti-ageing market to reach $108.5 billion by 2033. NAD+ has become one of its more marketable ideas. Supplements, after all, don’t sell themselves by saying the effects are modest and context-dependent.

And yet, dismissing NAD+ entirely would be missing the point. It is genuinely important. It plays a central role in how cells function, repair themselves, and respond to stress. Understanding it better could lead to meaningful advances in how we approach age-related diseases and metabolic disorders. The interest is not misplaced; it’s just occasionally over-interpreted.

If anything, NAD+ offers a useful lens through which to view modern health culture. It shows how quickly a complex biological concept can be translated into a consumer product, how eagerly people will adopt it, and how difficult it is to separate potential from promise.

In the end, NAD+ remains what it has always been: a molecule doing essential work, largely unnoticed, now briefly in the spotlight. The difference is that we’re paying attention. Whether that attention leads to better science or just better marketing is still an open question, and probably depends on who’s telling the story.

Either way, your cells are already using NAD+ right now, without asking for your opinion, your subscription, or your credit card. Which, in a landscape full of optimisation strategies, feels almost refreshingly honest.